Larvol Delta - Impact-of-Deucravacitinib-Treatment-on-Cardiovascular-RiskAssociated-Scores-and-Biomarkers-in-Patients-With-Active-Psoriatic-Arthritis-Results-From-Phase-3-Studies

Saphnelo (anifrolumab-fnia) - AstraZeneca

https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3570228

Ioannis Parodis, MD; PhD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next